World's Best Scientists 2026 revealed!
Jean-Pierre Bronowicki

Jean-Pierre Bronowicki

Overview

Jean-Pierre Bronowicki is affiliated with the University Hospital of Nancy in France. Their research primarily focuses on hepatology, epidemiology, pathology and forensic medicine, surgery, and pulmonary and respiratory medicine within the broader field of medicine. The scientist has produced a significant number of publications related to liver diseases and cancer mechanisms, contributing extensively to the understanding and treatment of hepatocellular carcinoma and liver disease diagnosis and treatment.

Their main topics of work include:

  • Hepatocellular Carcinoma Treatment and Prognosis
  • Liver Disease Diagnosis and Treatment
  • Hepatitis C virus research
  • Liver Disease and Transplantation
  • Hepatitis B Virus Studies
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Cancer Mechanisms and Therapy

Jean-Pierre Bronowicki has collaborated frequently with several co-authors over the course of their career. These include Nathalie Ganne-Carrié, Marc Bourlière, Victor de Lédinghen, Stanislas Pol, and Pierre Nahon, with each contributing to multiple joint publications.

Their published work appears predominantly in a range of scientific journals with a strong emphasis on hepatology and oncology fields. Frequent publication venues include:

  • Journal of Hepatology
  • JHEP Reports
  • Clinics and Research in Hepatology and Gastroenterology
  • Journal of Clinical Oncology
  • The Lancet

Some recent papers authored or co-authored by Jean-Pierre Bronowicki are:

  • Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial (2023, The Lancet)
  • Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial (2023, The Lancet Oncology)
  • Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (2024, Annals of Oncology)
  • Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study (2025, The Lancet)
  • Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status (2020, Journal of Hepatology)

Best Publications

  • Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

    Jordi Bruix;Shukui Qin;Philippe Merle;Alessandro Granito

  • Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.

    Christophe Hézode;Nicole Forestier;Geoffrey Dusheiko;Peter Ferenci

  • Regression of Splenic Lymphoma with Villous Lymphocytes after Treatment of Hepatitis C Virus Infection

    Olivier Hermine;François Lefrère;Jean-Pierre Bronowicki;Xavier Mariette

  • Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

    Valérie Vilgrain;Valérie Vilgrain;Helena Pereira;Eric Assenat;Boris Guiu

  • Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study

    Fabrice Carrat;Hélène Fontaine;Céline Dorival;Mélanie Simony

  • Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.

    Richard Moreau;Francois Durand;Thierry Poynard;Christian Duhamel

  • Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study.

    Caroline Charlier;Élodie Perrodeau;Alexandre Leclercq;Alexandre Leclercq;Benoît Cazenave

  • A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.

    Christophe Corpechot;Olivier Chazouillères;Alexandra Rousseau;Antonia Le Gruyer

  • Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications

    Pierre Nahon;Pierre Nahon;Valérie Bourcier;Richard Layese;Etienne Audureau

  • Patient-to-Patient Transmission of Hepatitis C Virus during Colonoscopy

    Jean-Pierre Bronowicki;Véronique Venard;Christine Botté;Nathalie Monhoven

  • Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890

    Christophe Hézode;Hélène Fontaine;Céline Dorival;Dominique Larrey

  • All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

    Michael Peter Manns;Stanislas B Pol;Ira M Jacobson;Patrick M Marcellin

  • Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities.

    Jean‐Claude Trinchet;Cendrine Chaffaut;Valérie Bourcier;Françoise Degos

  • Sulfate‐reducing bacteria in human feces and their association with inflammatory bowel diseases

    Julien Loubinoux;Julien Loubinoux;Jean-Pierre Bronowicki;Ines A.C. Pereira;Jean-Louis Mougenel

  • Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study

    Jorge A. Marrero;Masatoshi Kudo;Alan P. Venook;Sheng Long Ye

  • Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial

    Xavier Forns;Eric Lawitz;Stefan Zeuzem;Ed Gane

  • Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)

    Marc Bourlière;Jean Pierre Bronowicki;Victor de Ledinghen;Christophe Hézode

  • Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis

    Christophe Hézode;Helene Fontaine;Celine Dorival;Fabien Zoulim

  • Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)

    Vincent Leroy;Peter W Angus;Jean-Pierre Bronowicki;Gregory J Dore

  • Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: The ANRS HCEP-23 study

    Jean-Pierre Zarski;Nathalie Sturm;Jérôme Guechot;Adeline Paris

Frequent Co-Authors

Marc Bourlière
Marc Bourlière Hôpital Saint Joseph
Dominique Larrey
Dominique Larrey University of Montpellier
Stanislas Pol
Stanislas Pol Université Paris Cité
Christophe Hézode
Christophe Hézode Université Paris Cité
Albert Tran
Albert Tran Inserm : Institut national de la santé et de la recherche médicale
Victor de Ledinghen
Victor de Ledinghen Grenoble Alpes University
Patrick Marcellin
Patrick Marcellin Université Paris Cité
Philippe Mathurin
Philippe Mathurin University of Lille
Laurent Alric
Laurent Alric Federal University of Toulouse Midi-Pyrénées

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in medicine but seeking alternatives to the traditional path of medical school, there are a variety of flexible and rewarding online degree options. For those looking to enter the field quickly, consider accelerated LPN programs, which enable you to become a Licensed Practical Nurse in less time and start your healthcare career sooner.

For nurses wishing to specialize, there are options such as the shortest online pmhnp programs, ideal for those passionate about mental health and pursuing nurse practitioner roles.

Not all healthcare careers involve direct patient care. Students interested in the business and management side of healthcare should look into a health care administration online degree. For those aiming to advance further, a master's in healthcare administration online can lead to leadership positions across hospitals, clinics, and health organizations.

Each of these pathways offers the flexibility of online study and can open doors to fast-growing roles in the healthcare industry.

Best Scientists Citing Jean-Pierre Bronowicki

Trending Scientists

Recently Published Articles